Outcomes and survival following thoracic endovascular repair in patients with aortic aneurysms limited to the descending thoracic aorta.


Journal

Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113

Informations de publication

Date de publication:
20 Jun 2023
Historique:
received: 06 01 2023
accepted: 10 04 2023
medline: 22 6 2023
pubmed: 21 6 2023
entrez: 20 6 2023
Statut: epublish

Résumé

Thoracic endovascular aortic repair (TEVAR) is a well-established therapy for descending aortic aneurysms (DTA). There is a paucity of large series reporting the mid- and long-term outcomes from this era. The main aim of this study was to evaluate the outcomes of TEVAR with regards to the effect of aortic morphology and procedure-related variables on survival, reintervention and freedom from endoleaks. In this retrospective single center study, we evaluated the clinical outcomes among 158 consecutive patients with DTA than underwent TEVAR between 2006 and 2019 at our center. The cohort included 51% patients with device landing zones proximal to the subclavian artery and 25.9% patients undergoing an emergent or urgent TEVAR. The primary outcome was survival, and secondary outcomes were reintervention and occurrence of endoleaks. Median follow-up was 33 months [IQR 12 to 70] while 50 patients (30.6%) had longer than 5-year follow-up. With a median patient age of 74 years, post-operative Kaplan Meyer survival estimates were 94.3% (95%CI 90.8-98.0, SE 0.018%) at 30 days, 76.4% (95%CI 70.0-83.3, SE 0.034%) at one year and, 52.9% (95%CI 45.0-62.2, SE 0.043%) at five years. Freedom from reintervention at 30 days, one year, and five years was 92.9% (95%CI 89.0-97.1, SE 0.021%), 80.0% (95%CI 72.6-88.1, SE 0.039%), and 52.8% (95%CI 41.4-67.4, SE 0.065%), respectively. On cox regression analysis greater aneurysm diameter, and the use of device landing zones in aortic regions 0-1 were associated with an increased probability of all-cause mortality, and with reintervention during follow-up. Independent of aneurysm size undergoing urgent or emergent TEVAR was associated with higher mortality risk for the first three years post-operative but not on long-term follow-up. Larger aneurysms and those requiring stent-graft landing in aortic zones 0 or 1, are associated with higher risk for mortality and reintervention. There remains a need to optimize clinical management and device design for larger proximal aneurysms.

Sections du résumé

BACKGROUND BACKGROUND
Thoracic endovascular aortic repair (TEVAR) is a well-established therapy for descending aortic aneurysms (DTA). There is a paucity of large series reporting the mid- and long-term outcomes from this era. The main aim of this study was to evaluate the outcomes of TEVAR with regards to the effect of aortic morphology and procedure-related variables on survival, reintervention and freedom from endoleaks.
METHODS METHODS
In this retrospective single center study, we evaluated the clinical outcomes among 158 consecutive patients with DTA than underwent TEVAR between 2006 and 2019 at our center. The cohort included 51% patients with device landing zones proximal to the subclavian artery and 25.9% patients undergoing an emergent or urgent TEVAR. The primary outcome was survival, and secondary outcomes were reintervention and occurrence of endoleaks.
RESULTS RESULTS
Median follow-up was 33 months [IQR 12 to 70] while 50 patients (30.6%) had longer than 5-year follow-up. With a median patient age of 74 years, post-operative Kaplan Meyer survival estimates were 94.3% (95%CI 90.8-98.0, SE 0.018%) at 30 days, 76.4% (95%CI 70.0-83.3, SE 0.034%) at one year and, 52.9% (95%CI 45.0-62.2, SE 0.043%) at five years. Freedom from reintervention at 30 days, one year, and five years was 92.9% (95%CI 89.0-97.1, SE 0.021%), 80.0% (95%CI 72.6-88.1, SE 0.039%), and 52.8% (95%CI 41.4-67.4, SE 0.065%), respectively. On cox regression analysis greater aneurysm diameter, and the use of device landing zones in aortic regions 0-1 were associated with an increased probability of all-cause mortality, and with reintervention during follow-up. Independent of aneurysm size undergoing urgent or emergent TEVAR was associated with higher mortality risk for the first three years post-operative but not on long-term follow-up.
CONCLUSIONS CONCLUSIONS
Larger aneurysms and those requiring stent-graft landing in aortic zones 0 or 1, are associated with higher risk for mortality and reintervention. There remains a need to optimize clinical management and device design for larger proximal aneurysms.

Identifiants

pubmed: 37340389
doi: 10.1186/s13019-023-02285-3
pii: 10.1186/s13019-023-02285-3
pmc: PMC10280975
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

194

Informations de copyright

© 2023. The Author(s).

Références

Eur J Vasc Endovasc Surg. 2017 Jan;53(1):4-52
pubmed: 28081802
J Thorac Cardiovasc Surg. 2006 May;131(5):1087-94
pubmed: 16678594
J Vasc Surg. 2010 Sep;52(3):549-54; discussion 555
pubmed: 20598483
J Vasc Surg. 2022 Mar;75(3):833-841.e1
pubmed: 34506896
BMJ Open. 2021 Mar 4;11(3):e043323
pubmed: 33664076
J Vasc Surg. 2018 Feb;67(2):363-368
pubmed: 28847657
J Endovasc Ther. 2016 Apr;23(2):387-92
pubmed: 26802610
J Endovasc Ther. 2004 Dec;11 Suppl 2:II62-71
pubmed: 15760265
Eur J Vasc Endovasc Surg. 2019 Jun;57(6):788-794
pubmed: 30910493
Yonsei Med J. 2015 Jul;56(4):904-12
pubmed: 26069110
J Vasc Surg. 2021 Jan;73(1S):55S-83S
pubmed: 32628988
Circulation. 2010 Jun 29;121(25):2718-23
pubmed: 20547930
J Am Coll Cardiol. 2010 Mar 9;55(10):986-1001
pubmed: 20137879
Circulation. 2011 Jun 28;123(25):2938-45
pubmed: 21646499
J Vasc Surg. 2016 Oct;64(4):912-920.e1
pubmed: 27423338
J Vasc Surg. 2017 Aug;66(2):335-342
pubmed: 28366302
J Vasc Surg. 2008 May;47(5):1094-1098
pubmed: 18242941
Eur Heart J. 2014 Nov 1;35(41):2873-926
pubmed: 25173340
Health Technol Assess. 2022 Jan;26(6):1-166
pubmed: 35094747

Auteurs

Katharina Fankhauser (K)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Isaac Wamala (I)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Adam Penkalla (A)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Roland Heck (R)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
German Center for Cardiovascular Research (DHZK), Partner Site Berlin, Berlin, Germany.

Robert Hammerschmidt (R)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Volkmar Falk (V)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
German Center for Cardiovascular Research (DHZK), Partner Site Berlin, Berlin, Germany.
Translational Cardiovascular Technologies, Institute of Translational Medicine, Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland.

Semih Buz (S)

Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353, Berlin, Germany. Semih.Buz@dhzc-charite.de.
Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. Semih.Buz@dhzc-charite.de.
German Center for Cardiovascular Research (DHZK), Partner Site Berlin, Berlin, Germany. Semih.Buz@dhzc-charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH